Compare Stocks: APTO, TCRX, BCDA, and ALLR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.87 +0.4%	$1.22	$0.77 ▼ $1.84	$13.84M	0.57	125,584 shs	64,019 shs
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
BCDA BioCardia	$0.93 -6.4%	$1.06	$0.75 ▼ $1.80	$14.99M	0.62	324,609 shs	146,447 shs
TCRX TScan Therapeutics	$0.21 -2.8%	$0.49	$0.20 ▼ $2.57	$14.69M	1.15	728,918 shs	546,577 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+1.14%	-11.71%	-28.70%	-26.28%	-43.14%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
BCDA BioCardia	-2.91%	-6.58%	-8.31%	+13.02%	-34.42%
TCRX TScan Therapeutics	-7.52%	-20.12%	-31.34%	-76.09%	-90.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.87 +0.4%	$1.22	$0.77 ▼ $1.84	$13.84M	0.57	125,584 shs	64,019 shs
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
BCDA BioCardia	$0.93 -6.4%	$1.06	$0.75 ▼ $1.80	$14.99M	0.62	324,609 shs	146,447 shs
TCRX TScan Therapeutics	$0.21 -2.8%	$0.49	$0.20 ▼ $2.57	$14.69M	1.15	728,918 shs	546,577 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+1.14%	-11.71%	-28.70%	-26.28%	-43.14%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
BCDA BioCardia	-2.91%	-6.58%	-8.31%	+13.02%	-34.42%
TCRX TScan Therapeutics	-7.52%	-20.12%	-31.34%	-76.09%	-90.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	1,073.71% Upside
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
BCDA BioCardia	2.00	Hold	$25.00	2,596.29% Upside
TCRX TScan Therapeutics	2.13	Hold	$2.67	1,166.22% Upside

Current Analyst Ratings Breakdown

Latest APTO, TCRX, BCDA, and ALLR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/13/2026	TCRX TScan Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/12/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	43.42	N/A	N/A	$0.61 per share	1.43
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
BCDA BioCardia	$60K	233.96	N/A	N/A	$0.08 per share	11.59
TCRX TScan Therapeutics	$10.32M	1.38	N/A	N/A	$2.16 per share	0.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest APTO, TCRX, BCDA, and ALLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	BCDA BioCardia	-$0.15	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	TCRX TScan Therapeutics	-$0.18	N/A	N/A	N/A	$0.46 million	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
APTO Aptose Biosciences	N/A	1.05	1.05
BCDA BioCardia	N/A	2.09	2.09
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
APTO Aptose Biosciences	26.62%
BCDA BioCardia	20.57%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
APTO Aptose Biosciences	1.33%
BCDA BioCardia	17.40%
TCRX TScan Therapeutics	6.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	8	15.91 million	15.89 million	Not Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
BCDA BioCardia	21	15.14 million	12.51 million	Optionable
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable

APTO, TCRX, BCDA, and ALLR Headlines

Recent News About These Companies

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2026 | zacks.com

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026 | globenewswire.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

April 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, TCRX, BCDA, and ALLR Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$0.87 +0.00 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.19%)

As of 07:52 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

BioCardia NASDAQ:BCDA

$0.93 -0.06 (-6.37%)

Closing price 04:00 PM Eastern

Extended Trading

$0.99 +0.06 (+6.99%)

As of 07:39 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

TScan Therapeutics NASDAQ:TCRX

$0.21 -0.01 (-2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.21 +0.00 (+1.61%)

As of 07:42 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, TCRX, BCDA, and ALLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, TCRX, BCDA, and ALLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, TCRX, BCDA, and ALLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, TCRX, BCDA, and ALLR Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Aptose Biosciences NASDAQ:APTO

BioCardia NASDAQ:BCDA

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, TCRX, BCDA, and ALLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, TCRX, BCDA, and ALLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, TCRX, BCDA, and ALLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, TCRX, BCDA, and ALLR Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Aptose Biosciences NASDAQ:APTO

BioCardia NASDAQ:BCDA

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools